FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136418904> ?p ?o ?g. }

• W3136418904 endingPage "S502" @default.
• W3136418904 startingPage "S501" @default.
• W3136418904 abstract "Small cell lung cancer (SCLC) cells are highly dependent on oncogenic transcription factors (TF) such as ASCL1, NeuroD1 and NFIB, which support their growth. Lurbinectedin is a selective transcription protein-coding gene inhibitor, that causes the detachment of TF from target promoters. Moreover, in vivo studies have shown lurbinectedin affects the inflammatory microenvironment, by inducing a pro-apoptotic effect on tumor-associated macrophages (TAMs) and a specific inflammatory cytokines inhibition of production. Lurbinectedin was approved by the FDA for adults with metastatic SCLC with disease progression on or after platinum-based chemotherapy based on a single-arm, open-label study phase 2 basket trial.. The aim of this phase I/II study is to assess the safety, tolerability and preliminary efficacy of lurbinectedin in combination with pembrolizumab for the treatment of pts with SCLC in second line after relapse or progressive disease. The phase I stage is a dose escalation to select the recommended dose (RD) based on the safety observed after the administration of lurbinectedin in combination with pembrolizumab. The phase II stage will explore the clinical activity at the RD. This is a multicenter, open-label, single-arm, phase I/II study of lurbinectedin (iv) in combination with pembrolizumab (iv) in pts with relapsed or progressive SCLC (NCT04358237). In the phase I, cohorts of 3-6 pts with SCLC will be treated with escalating doses of PM01183 in combination with a fixed dose of pembrolizumab. In the phase II stage, a single expansion cohort of approximately 30 pts will be treated with lurbinectedin combined with pembrolizumab at the recommended dose (RD) determined during the phase I stage. Regardless of stage, pts will receive lurbinectedin in combination with pembrolizumab until progression, unacceptable toxicity, consent withdrawal or if not considered in their best interest to continue. Main inclusion criteria include: (a) pts with histologically confirmed diagnosis of SCLC whose disease has progressed after first-line chemotherapy-based regimen, (b) at least 4 weeks since the last anticancer therapy, (c) measurable or evaluable disease according to the Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v 1.1). Recruitment: 30 evaluable pts in the RD will be recruited to test the null hypothesis, 10% or less pts will respond, versus the alternative hypothesis, 30% or more pts will respond to treatment. Primary objectives: (i) the determination of maximum tolerated dose (MTD) and RD, and dose-limiting toxicities (DLTs) of lurbinectedin in combination with pembrolizumab, and (ii) to assess the efficacy of lurbinectedin in combination with pembrolizumab. Secondary objectives include: (i) to obtain preliminary information on clinical antitumor activity of this combination in pts with SCLC, (ii) to characterize antitumor activity of this combination as per RECIST 1.1 in terms of overall response rate (ORR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS), (iii) to characterize the safety profile and the plasma pharmacokinetics (PK) of the combination, (iv) to perform pharmacogenetic (PGt) and pharmacogenomic (PGx) analysis in tumor samples of pts. Current status active, not yet recruiting. SCLC, Lurbinectedin, Pembrolizumab" @default.
• W3136418904 created "2021-03-29" @default.
• W3136418904 creator A5031841276 @default.
• W3136418904 creator A5058240195 @default.
• W3136418904 creator A5061670520 @default.
• W3136418904 creator A5063866135 @default.
• W3136418904 creator A5090452503 @default.
• W3136418904 date "2021-03-01" @default.
• W3136418904 modified "2023-09-27" @default.
• W3136418904 title "P48.06 Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial" @default.
• W3136418904 doi "https://doi.org/10.1016/j.jtho.2021.01.876" @default.
• W3136418904 hasPublicationYear "2021" @default.
• W3136418904 type Work @default.
• W3136418904 sameAs 3136418904 @default.
• W3136418904 citedByCount "0" @default.
• W3136418904 crossrefType "journal-article" @default.
• W3136418904 hasAuthorship W3136418904A5031841276 @default.
• W3136418904 hasAuthorship W3136418904A5058240195 @default.
• W3136418904 hasAuthorship W3136418904A5061670520 @default.
• W3136418904 hasAuthorship W3136418904A5063866135 @default.
• W3136418904 hasAuthorship W3136418904A5090452503 @default.
• W3136418904 hasBestOaLocation W31364189041 @default.
• W3136418904 hasConcept C121608353 @default.
• W3136418904 hasConcept C126322002 @default.
• W3136418904 hasConcept C143998085 @default.
• W3136418904 hasConcept C197934379 @default.
• W3136418904 hasConcept C2776256026 @default.
• W3136418904 hasConcept C2777701055 @default.
• W3136418904 hasConcept C2778375690 @default.
• W3136418904 hasConcept C2780057760 @default.
• W3136418904 hasConcept C31760486 @default.
• W3136418904 hasConcept C502942594 @default.
• W3136418904 hasConcept C535046627 @default.
• W3136418904 hasConcept C71924100 @default.
• W3136418904 hasConceptScore W3136418904C121608353 @default.
• W3136418904 hasConceptScore W3136418904C126322002 @default.
• W3136418904 hasConceptScore W3136418904C143998085 @default.
• W3136418904 hasConceptScore W3136418904C197934379 @default.
• W3136418904 hasConceptScore W3136418904C2776256026 @default.
• W3136418904 hasConceptScore W3136418904C2777701055 @default.
• W3136418904 hasConceptScore W3136418904C2778375690 @default.
• W3136418904 hasConceptScore W3136418904C2780057760 @default.
• W3136418904 hasConceptScore W3136418904C31760486 @default.
• W3136418904 hasConceptScore W3136418904C502942594 @default.
• W3136418904 hasConceptScore W3136418904C535046627 @default.
• W3136418904 hasConceptScore W3136418904C71924100 @default.
• W3136418904 hasIssue "3" @default.
• W3136418904 hasLocation W31364189041 @default.
• W3136418904 hasOpenAccess W3136418904 @default.
• W3136418904 hasPrimaryLocation W31364189041 @default.
• W3136418904 hasRelatedWork W2415023131 @default.
• W3136418904 hasRelatedWork W2786497694 @default.
• W3136418904 hasRelatedWork W2898071776 @default.
• W3136418904 hasRelatedWork W3030961199 @default.
• W3136418904 hasRelatedWork W3042132061 @default.
• W3136418904 hasRelatedWork W3159027554 @default.
• W3136418904 hasRelatedWork W3175277114 @default.
• W3136418904 hasRelatedWork W3215044659 @default.
• W3136418904 hasRelatedWork W4205284999 @default.
• W3136418904 hasRelatedWork W4293776606 @default.
• W3136418904 hasVolume "16" @default.
• W3136418904 isParatext "false" @default.
• W3136418904 isRetracted "false" @default.
• W3136418904 magId "3136418904" @default.
• W3136418904 workType "article" @default.